Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Atopic Dermatitis Eczema · Plaque Psoriasis · ARQT

Arcutis Biotherapeutics

Arcutis Biotherapeutics patent portfolio — 30 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
2945 Townsgate Rd, Westlake Village, California 91361, US HQ
2016 Founded
427 Employees
Public company Type
ARQT · NYSE Ticker
Company details
Status
Public
HQ
2945 Townsgate Rd, Westlake Village, California 91361, US
Founded
2016
Employees
427
Programs
27
Drugs
3
Patents
30
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Arcutis Biotherapeutics patents

30 pharmaceutical patents indexed for Arcutis Biotherapeutics. 0 expire within 24 months.

Arcutis Biotherapeutics has 30 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

30 patents

Patent portfolio

  1. US 12390453

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12336983

    Inhibition of crystal growth of roflumilast

    Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12329751

    Topical roflumilast formulation having antifungal properties

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12310956

    Topical roflumilast formulation having improved delivery and plasma half-life

    Expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12257242

    Inhibition of crystal growth of roflumilast

    Expires Mon Mar 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12220409

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12161643

    Stable formulations of SHR0302

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12144802

    Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12083122

    Laureth-4 containing topical formulations

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12053481

    Compositions and methods for deep dermal drug delivery

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12042558

    Method and formulation for improving roflumilast skin penetration lag time

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12042487

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12016848

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Jun 20 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12011437

    Roflumilast formulations with an improved pharmacokinetic profile

    Expires Mon Jun 13 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12005051

    Topical roflumilast formulation having improved delivery and plasma half life

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12005052

    Topical roflumilast formulation having improved delivery and plasma half-life

    Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11992480

    Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

    Expires Mon May 23 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11819496

    Topical roflumilast formulation having improved delivery and plasma half-life

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11793796

    Inhibition of crystal growth of roflumilast

    Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11730740

    Laureth-4 containing topical formulations

    Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11707454

    Topical roflumilast formulation having antifungal properties

    Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11628177

    Compositions and methods for deep dermal drug delivery

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11534493

    Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents

    Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11129818

    Topical roflumilast formulation having improved delivery and plasma half life

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10940142

    Inhibition of crystal growth of roflumilast

    Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10172841

    Inhibition of crystal growth of roflumilast

    Expires Mon Jan 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10105354

    Inhibition of crystal growth of roflumilast

    Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9907788

    Inhibition of crystal growth of roflumilast

    Expires Mon Mar 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9895359

    Inhibition of crystal growth of roflumilast

    Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9884050

    Inhibition of crystal growth of roflumilast

    Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Arcutis Biotherapeutics have?

30 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Arcutis Biotherapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.